Avandia survives FDA panel vote, but not unscathed

Avandia survives FDA panel vote, but not unscathed
 
Expert comment from Datamonitor healthcare analyst Christine Henry
 
New York, NY - July 15, 2010 - "The next step for Avandia will follow the FDA's action on the advisory panel's recommendations. In the absence of stronger evidence for risk, there may be an incentive to keep Avandia on the market to allow for wider clinician choice, a view expressed in panel discussions. Even if the FDA does not follow the panel's advice to withdraw or restrict prescribing of Avandia, physician and patient concerns about safety and litigation, and the availability of alternative therapies for most diabetics are likely to lead to continuing decline in sales of Avandia."
 
"Avandia's decline further opens the door for the antidiabetics that have already filled the gap created after the first Avandia safety scare in 2007 - class leader Actos as well as Merck's blockbuster DPP-4 drug Januvia (sitagliptin). With Avandia hit by safety fears and Actos approaching patent expiry in 2011, there is also the possibility for newer drug classes to seize market share, maintaining the attractiveness of type 2 diabetes as a commercial and clinical target."
 
Ends
 
 
Notes for editors
Christine Henry is available for comment.
To arrange an interview or for further details regarding this release please contact Alicia Barrios in the Datamonitor press office on +1 570 687 9319, or email [email protected]
 
For UK, please contact Joe Dixonon + 44 (0)161 238 4083. For Asia-Pacific, please contact Tanisha Kaul on +61 (0) 9601 6723. For India/Middle-East, please contact Aartee Sundheep on + 91 (40) 6672 9586
 
ABOUT DATAMONITOR
The Datamonitor Group (www.datamonitor.com) is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Sourcing, Technology and Telecoms industries. Combining our industry knowledge and experience, we assist more than 6,000 of the world's leading companies in making better strategic and operational decisions.  
 

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.